ECKERT & ZIEGLER BG 
By Seneffe, Belgium, November 6, 2013, Eckert & Ziegler BEBIG is proud to announce the acquisition of Mick Radio Nuclear Instruments, Inc. (MRNI), which has been a pioneer and leader in the development of applicators for brachytherapy for more than four decades. The globally active company generated sales of ?4 million in fiscal year 2012/2013.
Mick Radio Nuclear Instruments was founded in 1972 and is situated in Mount Vernon, New York. The U.S. company offers a wide portfolio of applicators for low dose rate (LDR) and high dose rate (HDR) brachytherapy as well as products and accessories for external beam and total body irradiation. Furthermore, it owns various patents for renowned applicators, such as the Mick® Applicator for LDR brachytherapy, with over 3,000 models in use worldwide. The company, led by Felix Mick, has shaped the brachytherapy market with its groundbreaking inventions over the last 40 years.
Having already acquired the brachytherapy business of Biocompatibles Inc., a subsidiary of BTG plc., the purchase of Mick Radio Nuclear Instruments is a further step in the Eckert & Ziegler BEBIG's efforts to expand into the U.S. brachytherapy market and to gain new customers. Additionally, it allows the company to enhance its existing product portfolio with further advanced products.
"We have been working together with Mick Radio Nuclear Instruments for many years and have always been impressed by the company's high level of innovation," said Dr. Edgar Löffler, Chief Executive Officer of Eckert & Ziegler BEBIG. "Besides Mick Radio Nuclear Instruments' international business, the company is deeply respected in the American brachytherapy community and will be a further basis for us to expand into the U.S. Together with the acquired brachytherapy products of Bicompatibles, Inc. Eckert & Ziegler BEBIG will be able to provide a full brachytherapy portfolio that is characterized by unique products and features. We also see many potential synergies linked with both recent acquisitions for the U.S. market entry," Dr. Löffler added.
Felix and Verena Mick will continue to support the company in advisory capacity.
About Mick Radio Nuclear Instruments, Inc.
Mick Radio Nuclear Instruments, Inc., known internationally for its 40 years of service to the radiation therapy and brachytherapy community, provides top-quality, state-of-the-art brachytherapy technology to confront the challenges faced in the fight against cancer.
For much of the past 40 years, Mick Radio Nuclear Instruments, Inc.'s commitment to prostate brachytherapy has resonated throughout the world. It remains a strong and viable technology with proven excellent clinical outcomes at reasonable cost.
Mick Radio-Nuclear Instruments, Inc. continues to face daily challenges within the industry, developing new brachytherapy applicators compatible for use with CT and MRI. The company is proud of its accomplishments and humbly acknowledges the abundant opportunities it has had to work with so many esteemed and prominent radiation oncologists and medical physicists around the world.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe, in the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line. The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 200 people. The company has been listed on the Euronext stock exchange since April 1997.
Contact:
Claudia Wolf
Head of Marketing
Tel: +49 (0) 30 94 10 84 272
marketing@bebig.eu:
https://mce_host/hugin/marketing@bebig.eu
Karolin Riehle
Investor Relations
Tel.: +32 (0) 64 520 808
ir@bebig.eu:
https://mce_host/hugin/ir@bebig.eu
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
